Source link : https://www.newshealth.biz/health-news/atopic-dermatitis-control-on-biologic-persists-over-3-years/
AMSTERDAM — For patients with atopic dermatitis (AD) who responded to the anti-interleukin (IL)-13 monoclonal antibody lebrikizumab in the pivotal trials, the level of response, including 90% skin clearance, has generally remained unchanged among those followed up for an additional 2 years, according to the latest data from an extension study. At the end of […]
Author : News Health
Publish date : 2024-09-30 11:21:48
Copyright for syndicated content belongs to the linked Source.